Certara updates trial simulator software

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/BrianAJackson)
(Image: Getty/BrianAJackson)

Related tags Certara Adaptive designs Clinical trial

Certara has launched version 2.3 of its Trial Simulator software, which allows users to model and simulate different clinical trial scenarios – and supports the implementation of adaptive design.

The Trial Simulator software supports a variety of trial designs, including parallel, n-by-n Latin square, and crossover designs with any number of treatment groups and periods, explained Certara​ Chief Commercial Officer Ellen Leinfuss.

“The study enrolls subjects from one or more study centers, each of which may draw subjects from a different subpopulation with different covariate distributions,”​ she told us.

“Subjects may be screened for trial inclusion based on covariate values and/or responses measured during an optional lead-in phase.

“Active phase treatments and observations may include any number of doses and measurements, scheduled at specific times or using a recurring cycle of times. Trial Simulator supports adaptive dosing schemes and covariate or response based dose adjustments,”​ Leinfuss said.

The US Food and Drug Administration (FDA) recently released draft guidance on the use of adaptive design in clinical trials​. The adaptive design draft guidance advises industry on the types of information FDA needs to evaluate the results from clinical trials with adaptive designs. This includes Bayesian adaptive designs and complex designs relying on computer simulations.

The European Medicines Agency (EMA) also recently updated​ its first-in-human (FIH) recommendations, which Certara’s quantitative systems pharmacology (QSP) approach builds on. The company earlier this year outlined​ the role of QSP in FIH clinical trial design in a “Letter to the Editor.” The EMA responded, welcoming the initiative shown and encouraging the use of mechanistic models. 

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more